Emergent BioSolutions Inc. (EBS)
Automate Your Wheel Strategy on EBS
With Tiblio's Option Bot, you can configure your own wheel strategy including EBS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EBS
- Rev/Share 17.6471
- Book/Share 10.1599
- PB 0.624
- Debt/Equity 1.2045
- CurrentRatio 6.3164
- ROIC -0.0871
- MktCap 344121252.0
- FreeCF/Share 1.7353
- PFCF 3.6454
- PE -2.6208
- Debt/Assets 0.4668
- DivYield 0
- ROE -0.2727
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EBS | H.C. Wainwright | -- | Buy | -- | $15 | Dec. 30, 2024 |
| Initiation | EBS | Rodman & Renshaw | -- | Buy | -- | $16 | Aug. 22, 2024 |
News
5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors would do well to monitor broker-favored stocks like BTSG, BYON, ACDVF, DINO, and EBS for high returns.
Read More
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Frank Vargo - Vice President, Assistant Treasurer Joe Papa - President and Chief Executive Officer Rich Lindahl - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by.
Read More
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago.
Read More
Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025
Published: April 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 7, 2025, at 5:00 pm eastern time to discuss the financial results for the first quarter of 2025.
Read More
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance manufacturing facility to Syngene International, a leading global contract research, development, and manufacturing organization, for a total value of $36.5 million. The Bayview site includes manufacturing, laboratory, warehousing and office space, and is fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
Read More
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
Published: March 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2024.
Read More
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025 Separately, Company leaders will attend and present at J.P. Morgan's 2025 Leveraged Finance Conference on February 24, 2025
Read More
About Emergent BioSolutions Inc. (EBS)
- IPO Date 2006-11-15
- Website https://www.emergentbiosolutions.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
- Employees 900